Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has reiterated a Buy rating on OncoCyte (NASDAQ:OCX) and maintained a price target of $4.25.
May 16, 2024 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson has reiterated a Buy rating on OncoCyte (NASDAQ:OCX) and maintained a price target of $4.25.
The reiteration of a Buy rating and the maintenance of a $4.25 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100